Home » Healthcare » Pharmaceuticals » Heparin Market

Heparin Market By Product (Unfragmented Heparin, Low Molecular Weight Heparin and Ultra-Low Molecular Weight Heparin), By Route of Administration (Subcutaneous and Intravenous) – Growth, Future Prospects & Competitive Analysis, 2017 – 2025

Summary
Table Of Content

Market Insights

The International Society on Thrombosis and Hemostasis 2017 report has stated the global incidence rate of venous thromboembolism to be 2 per 1000 persons. The risk factors associated with venous thromboembolism are prolonged hospital stays, cancer chemotherapy, smoking, alcohol consumption, and pregnancy. Heparin has excellent plasma protein binding properties. It has been found to be effective in the treatment of Parkinson’s disease via cathepsin-D activity. Heparin, being a glycosaminoglycan, has been found to reduce inflammation in rheumatoid arthritis and acute pancreatitis.

The report titled “Heparin Market” covers product segments, including unfragmented heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The routes of administration are subcutaneous and intravenous. Data forecasting and market estimation are covered to understand the latest trend in the products and route of administration segments.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market size and data forecasts are covered in the geography segment to understand the attractive investment proposition by geography.

Company profiles cover important information such as recent news coverage, business information, and product portfolios. The product portfolio gives a clear understanding of the recent trend present in the heparin market. Recent news covers the latest launch of a value-added heparin product and technological developments in the production of synthetic heparin. Market Assessment and data forecasts elucidate the existing business milieu in the global heparin market. The ace players involved in the production of heparin are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Based on product, the global heparin market is categorized into:

Unfractionated Heparin
Heparin with a Low Molecular Weight
Ultra-Low Molecular Weight Heparin

Heparin is an anticoagulant prescribed for the treatment of venous complications such as arterial thromboembolism, deep vein thrombosis, and pulmonary embolism. It is produced by the mast cells and basophils and binds to the enzyme antithrombin III, which further causes the inactivation of the blood clotting factor thrombin. Heparin is produced from the mucosal tissues of slaughtered porcine and bovine animals. It is present in the World Health Organization’s list of essential medicines, which demonstrates its importance in treatment. The low molecular weight represents the largest market share in the product segment due to its enhanced bioavailability and lower subcutaneous dosing frequency for complications like venous thromboembolism.

Additionally, the most important advantage of low molecular weight heparin is the reduced risk of heparin-induced thrombocytopenia. On the other hand, ultra-low molecular weight heparin has enhanced safety and efficacy due to its structural configuration, which promotes depolymerization. The medicinal application of ultra-low molecular weight heparin is being driven by rising demand as a therapeutic agent providing thromboprophylaxis in cancer patients undergoing surgery. Top players in the heparin market are Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA.

Based on the route of administration, the heparin market is categorized into:

Subcutaneous
Intravenous

The biological half-life of fragmented heparin is 1-2 hours after infusion, and low molecular weight heparin has a half-life four times longer than that of fragmented heparin. Proper caution needs to be taken while considering the dose specifications of heparin, as there are severe side effects of overdosing. Protamine sulfate has been useful to a certain extent in reversing the heparin overdose effect, but logically it is not possible to determine the blood concentration of heparin owing to its excellent plasma protein binding. The subcutaneous route is the most preferred route owing to its enhanced safety, shorter administration time, and relatively lower cost. It is useful in pregnant women, who have an increased risk for venous thromboembolism, and in patients undergoing reproductive immunology treatment. The intravenous route has advantages such as a quick onset of action and is the preferred route of choice in open heart surgeries, kidney dialysis, and blood transfusion.

For the purpose of this study, the global heparin market is categorized into the following regional and country-specific markets:

North America
- U.S.
- Canada
Europe
- Germany
- France
- Italy
- U.K.
- Russia
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

The National Center on Birth Defects and Developmental Disabilities has cited that every year in the United States, around 900,000 people suffer from venous thromboembolism (DVT or PE with a prevalence of 1 to 2 per 1,000 people. Approximately 10% to 30% of citizens die within a month of diagnosis, and venous thromboembolism is the leading cause of death in approximately 25% of DVT or PE patients. North America owns the largest market share in heparin products due to the increasing number of patients suffering from DVT and PE and the presence of top players actively engaged in the research and development of heparin products.

According to European Union statistics, the rising prevalence of coagulation disorders results in the death of approximately half a million EU citizens each year. Furthermore, the European Medical Agency’s supportive regulatory environment for synthetic heparin products propels the European heparin market’s growth. The patent expiration of low molecular weight heparin will boost the generic market in the Asia Pacific, resulting in a significant increase in heparin products. The World Health Organization has stated that the major cause of death in Asia and the Pacific regarding clotting disorders is pulmonary embolism.

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted

Chapter 2. Executive Summary
2.1. Global Heparin Market Portraiture
2.1.1. Global Heparin Market, by Product, 2016 (Value %)
2.1.2. Global Heparin Market, by Route of Administration, 2016 (Value %)
2.1.3. Global Heparin Market, by Geography, 2016 (Value %)

Chapter 3. Heparin Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography
3.6. Top 3 Countries: Global Heparin Market, 2015-2025 (US$ Mn)
3.7. Competitive Landscape : Global Heparin Market, by Key Players, 2015-2025 (US$ Mn)

Chapter 4. Global Heparin Market, by Product, 2015 – 2025 (US$ Mn)
4.1. Overview
4.2. Attractive Investment Proposition: Global Heparin Market, by Product, 2016
4.3. Unfractionated Heparin
4.4. Low Molecular Weight Heparin
4.5. Ultra-Low Molecular Weight Heparin

Chapter 5. Global Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
5.1. Overview
5.1.1. Attractive Investment Proposition: Global Heparin Market, by Route of Administration, 2016
5.2. Subcutaneous
5.3. Intravenous

Chapter 6. Global Heparin Market, by Geography, 2015 – 2025 (US$ Mn)
6.1. Overview
6.2. North America Heparin Market Analysis, 2015 – 2025
6.2.1. North America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.2.2. North America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.2.3. North America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Heparin Market Analysis, 2015 – 2025
6.3.1. Europe Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.3.2. Europe Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.3.3. Europe Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Heparin Market Analysis, 2015 – 2025
6.4.1. Asia Pacific Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.4.2. Asia Pacific Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.4.3. Asia Pacific Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. India
6.4.3.4. Rest of Asia Pacific
6.5. Latin America Heparin Market Analysis, 2015 – 2025
6.5.1. Latin America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.5.2. Latin America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.5.3. Latin America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa Heparin Market Analysis, 2015 – 2025
6.6.1. Middle East and Africa Heparin Market, by Product, 2015 – 2025 (US$ Mn)
6.6.2. Middle East and Africa Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
6.6.3. Middle East and Africa Heparin Market, by Region, 2015 – 2025 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East and Africa

Chapter 7. Company Profiles
7.1. Aspen Holdings
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Baxter International, Inc.
7.3. B. Braun Melsungen AG
7.4. Dr. Reddy’s Laboratories Ltd.
7.5. Fresenius SE & Co. KGaA
7.6. Leo Pharma A/S
7.7. Pfizer, Inc.
7.8. Sanofi AG
7.9. Syntex S.A.
7.10. Teva Pharmaceutical Industries Ltd.

List of Figures

FIG. 1 Heparin: Market Segmentation
FIG. 2 Global Heparin Market Share, by Product, 2016 (Value %)
FIG. 3 Global Heparin Market Share, by Route of Administration, 2016 (Value %)
FIG. 4 Global Heparin Market Share, by Geography, 2016 (Value %)
FIG. 5 Attractive Investment Proposition, by Geography
FIG. 6 Market Competition Landscape, by Key Players, 2016
FIG. 7 Global Unfragmented Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Low Molecular Weight Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Ultra-Low Molecular Weight Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Subcutaneous Route of Administration Market, 2015 – 2025 (US$ Mn)
FIG. 11 Global Intravenous Route of Administration Market, 2015 – 2025 (US$ Mn)
FIG. 12 U.S. Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 13 Canada Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 14 U.K. Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 15 Germany Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 16 Rest of Europe Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 17 Japan Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 18 China Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 19 India Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 20 Rest of Asia Pacific Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 21 Brazil Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 22 Mexico Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 23 Rest of Latin America Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 24 GCC Heparin Market, 2015 – 2025 (US$ Mn)
FIG. 25 Rest of Middle East and Africa Heparin Market, 2015 – 2025 (US$ Mn)

List of Tables

TABLE 1 Global Heparin Market Portraiture
TABLE 2 Global Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 3 Global Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 4 Global Heparin Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 6 North America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 7 North America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 8 Europe Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 9 Europe Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 10 Europe Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Asia Pacific Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 12 Asia Pacific Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 13 Asia Pacific Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 14 Latin America Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 15 Latin America Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 16 Latin America Heparin Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 17 Middle East and Africa Heparin Market, by Product, 2015 – 2025 (US$ Mn)
TABLE 18 Middle East and Africa Heparin Market, by Route of Administration, 2015 – 2025 (US$ Mn)
TABLE 19 Middle East and Africa Heparin Market, by Region, 2015 – 2025 (US$ Mn)
TABLE 20 Aspen Holdings: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 21 Baxter International, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 22 B.Braun Melsungen AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 23 Dr. Reddy’s Laboratories Ltd: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 24 Fresenius SE & Co. KGaA: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 25 LEO Pharma A/S: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 26 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 27 Sanofi AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 28 Syntex S.A.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)
TABLE 29 Teva Pharmaceutical Industries Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Heparin Market?

The market for Heparin Market is expected to reach US$ 14,853.1 Mn by 2025.

What is the Heparin Market CAGR?

The Heparin Market is expected to see significant CAGR growth over the coming years, at 7.21%.

What is the Forecast period considered for Heparin Market?

The report is forecasted from 2017-2025.

What is the base year considered for Heparin Market?

The base year of this report is 2016.

Who are the major players in this market?

Aspen Holdings, Teva Pharmaceutical Industries Ltd., Baxter International, Inc., Syntex S.A., B. Braun Melsungen AG, Sanofi AG, Dr. Reddy’s Laboratories Ltd., Pfizer, Inc., LEO Pharma A/S., and Fresenius SE & Co. KGaA. are some of the major players in the global market.

Purchase Options

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –